Correlation Between SCANDMEDICAL SOLDK and MagnaChip Semiconductor

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both SCANDMEDICAL SOLDK and MagnaChip Semiconductor at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining SCANDMEDICAL SOLDK and MagnaChip Semiconductor into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between SCANDMEDICAL SOLDK 040 and MagnaChip Semiconductor Corp, you can compare the effects of market volatilities on SCANDMEDICAL SOLDK and MagnaChip Semiconductor and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in SCANDMEDICAL SOLDK with a short position of MagnaChip Semiconductor. Check out your portfolio center. Please also check ongoing floating volatility patterns of SCANDMEDICAL SOLDK and MagnaChip Semiconductor.

Diversification Opportunities for SCANDMEDICAL SOLDK and MagnaChip Semiconductor

-0.08
  Correlation Coefficient

Good diversification

The 3 months correlation between SCANDMEDICAL and MagnaChip is -0.08. Overlapping area represents the amount of risk that can be diversified away by holding SCANDMEDICAL SOLDK 040 and MagnaChip Semiconductor Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on MagnaChip Semiconductor and SCANDMEDICAL SOLDK is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on SCANDMEDICAL SOLDK 040 are associated (or correlated) with MagnaChip Semiconductor. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of MagnaChip Semiconductor has no effect on the direction of SCANDMEDICAL SOLDK i.e., SCANDMEDICAL SOLDK and MagnaChip Semiconductor go up and down completely randomly.

Pair Corralation between SCANDMEDICAL SOLDK and MagnaChip Semiconductor

Assuming the 90 days horizon SCANDMEDICAL SOLDK 040 is expected to under-perform the MagnaChip Semiconductor. But the stock apears to be less risky and, when comparing its historical volatility, SCANDMEDICAL SOLDK 040 is 1.16 times less risky than MagnaChip Semiconductor. The stock trades about -0.05 of its potential returns per unit of risk. The MagnaChip Semiconductor Corp is currently generating about -0.03 of returns per unit of risk over similar time horizon. If you would invest  412.00  in MagnaChip Semiconductor Corp on September 18, 2024 and sell it today you would lose (34.00) from holding MagnaChip Semiconductor Corp or give up 8.25% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy100.0%
ValuesDaily Returns

SCANDMEDICAL SOLDK 040  vs.  MagnaChip Semiconductor Corp

 Performance 
       Timeline  
SCANDMEDICAL SOLDK 040 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days SCANDMEDICAL SOLDK 040 has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest fragile performance, the Stock's basic indicators remain stable and the current disturbance on Wall Street may also be a sign of long-run gains for the company stockholders.
MagnaChip Semiconductor 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days MagnaChip Semiconductor Corp has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, MagnaChip Semiconductor is not utilizing all of its potentials. The newest stock price uproar, may contribute to short-horizon losses for the private investors.

SCANDMEDICAL SOLDK and MagnaChip Semiconductor Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with SCANDMEDICAL SOLDK and MagnaChip Semiconductor

The main advantage of trading using opposite SCANDMEDICAL SOLDK and MagnaChip Semiconductor positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if SCANDMEDICAL SOLDK position performs unexpectedly, MagnaChip Semiconductor can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MagnaChip Semiconductor will offset losses from the drop in MagnaChip Semiconductor's long position.
The idea behind SCANDMEDICAL SOLDK 040 and MagnaChip Semiconductor Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.

Other Complementary Tools

Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Stocks Directory
Find actively traded stocks across global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance